The latest price target for ESSA Pharma (NASDAQ:EPIX) was reported by Piper Sandler on November 4, 2024. The analyst firm set a price target for $2.00 expecting EPIX to rise to within 12 months (a possible 24.22% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for ESSA Pharma (NASDAQ:EPIX) was provided by Piper Sandler, and ESSA Pharma downgraded their neutral rating.

There is no last upgrade for ESSA Pharma

The last downgrade for ESSA Pharma Inc happened on November 4, 2024 when Piper Sandler changed their price target from $15 to $2 for ESSA Pharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ESSA Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ESSA Pharma was filed on November 4, 2024 so you should expect the next rating to be made available sometime around November 4, 2025.

While ratings are subjective and will change, the latest ESSA Pharma (EPIX) rating was a downgraded with a price target of $15.00 to $2.00. The current price ESSA Pharma (EPIX) is trading at is $1.61, which is out of the analyst’s predicted range.